You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Pulmonology

Eosinophils as a Biomarker for Type 2 Asthma

Dr. Elliot Israel presents the utility of eosinophils as a biomarker of type 2 inflammation and their role in the disease burden of asthma.
Elliot Israel
MD
Elliot Israel

Learning objectives

  • Understand the role of eosinophils as a diagnostic, predictive, and prognostic marker of severe asthma

Description

Elliot Israel, MD, discusses the diagnostic, predictive, and prognostic role of eosinophils as a biomarker of type 2 inflammation in asthma.

Tags
type 2 inflammationbiomarkerscorticosteroidseosinophils
MAT-GLB-2407367 - 1.0 - 11/2024

About this expert

Pulmonology

Elliot Israel

MD

Director of the Respiratory Therapy Department, Director of Clinical Research in the Pulmonary and Critical Care Medicine Division, Gloria M. and Anthony C. Simboli and Distinguished Chair in Asthma Research | Brigham and Women’s Hospital, Boston, United States

See author’s profile
Elliot Israel

Related resources

ERS 2023 | Adult Asthma Symposium: Mini Debate
Pulmonology
expert video

ERS 2023 | Adult Asthma Symposium: Mini Debate

ERS 2023 | Adult Asthma Symposium: Panel Discussion
Pulmonology
expert video

ERS 2023 | Adult Asthma Symposium: Panel Discussion

ERS 2023 | Advancing Asthma Management Beyond Control
Pulmonology
expert video

ERS 2023 | Advancing Asthma Management Beyond Control

ERS 2023 | Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma
Pulmonology
expert video

ERS 2023 | Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma

ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma
Pulmonology
expert video

ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma

ERS 2023 | Evolving Patient Care: From Symptom Control to On-Treatment ​Clinical Remission​
Pulmonology
expert video

ERS 2023 | Evolving Patient Care: From Symptom Control to On-Treatment ​Clinical Remission​

ERS 2023 | How Achievable Is Clinical Remission on Biologic Therapy?
Pulmonology
expert video

ERS 2023 | How Achievable Is Clinical Remission on Biologic Therapy?

ERS 2023 | On-Therapy Remission in Pediatric Asthma: Where Are We Today?
Pulmonology
expert video

ERS 2023 | On-Therapy Remission in Pediatric Asthma: Where Are We Today?

ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion
Pulmonology
expert video

ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion

ERS 2023 | Progression of Underlying Disease in Pediatric Severe Asthma
Pulmonology
expert video

ERS 2023 | Progression of Underlying Disease in Pediatric Severe Asthma

ERS 2023 | Type 2 Biomarkers as Predictive and Prognostic Tools to Guide Management
Pulmonology
expert video

ERS 2023 | Type 2 Biomarkers as Predictive and Prognostic Tools to Guide Management

How Can Biologics Improve Lung Function in Pediatric Severe Asthma?
Pulmonology
expert video

How Can Biologics Improve Lung Function in Pediatric Severe Asthma?

GINA Asthma Decision Tree
Pulmonology
videoanimation

GINA Asthma Decision Tree

EAACI 2023 | Pediatric Severe Asthma: Why Lung Function Matters
Pulmonology
expert video

EAACI 2023 | Pediatric Severe Asthma: Why Lung Function Matters

Asthma White Board Video
Pulmonology
videoanimation

Asthma White Board Video

Type 2 Inflammation Underpins Pediatric Severe Asthma
Pulmonology
Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

Why Is It Important to Assess Lung Function in Pediatric Severe Asthma Patients?
Pulmonology
expert video

Why Is It Important to Assess Lung Function in Pediatric Severe Asthma Patients?

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age
Pulmonology
interactivity

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

GOLD 2024 Diagnosis and Assessment of COPD
Pulmonology
expert video

GOLD 2024 Diagnosis and Assessment of COPD

Importance of Lung Function Assessment in Pediatric Asthma Patients
Pulmonology
videoanimation

Importance of Lung Function Assessment in Pediatric Asthma Patients

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?
Pulmonology
Podcast

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

Lung Function Assessment Is a Fundamental Component of Optimal Asthma Care
Pulmonology
videoanimation

Lung Function Assessment Is a Fundamental Component of Optimal Asthma Care

How Can Poor Lung Function Impact Asthma Burden in Pediatric Patients?
Pulmonology
videoanimation

How Can Poor Lung Function Impact Asthma Burden in Pediatric Patients?

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission
Pulmonology
expert video

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

EAACI 2024 Emerging Definitions of Clinical Remission and Achieving Clinical Remission With Biologics for Patients With Asthma
Pulmonology
expert video

EAACI 2024 Emerging Definitions of Clinical Remission and Achieving Clinical Remission With Biologics for Patients With Asthma

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care
Pulmonology
expert video

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma
Pulmonology
Podcast

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Eosinophils as a Biomarker for Type 2 Asthma
Pulmonology
expert video

Eosinophils as a Biomarker for Type 2 Asthma

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13
Pulmonology
expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

ERS 2024 | Understanding the Complex Pathophysiology of COPD
Pulmonology
expert video

ERS 2024 | Understanding the Complex Pathophysiology of COPD

COPD and Asthma: What's the Difference and Is There a Link?
Pulmonology
interactivity

COPD and Asthma: What's the Difference and Is There a Link?

Type 2 Inflammation Digital Assessment Tool
Pulmonology
interactivity

Type 2 Inflammation Digital Assessment Tool

On-Treatment Asthma Remission: Moving Beyond Control
Pulmonology
interactivity

On-Treatment Asthma Remission: Moving Beyond Control

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity
Pulmonology
interactivity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

ERS 2023 | The Impact of Type 2 Inflammation on COPD: Examining Its Role in Disease Pathophysiology
Pulmonology
expert video

ERS 2023 | The Impact of Type 2 Inflammation on COPD: Examining Its Role in Disease Pathophysiology

GOLD 2023 | Beyond a One Size Fits All Approach: Recognizing the Heterogeneity of COPD
Pulmonology
expert video

GOLD 2023 | Beyond a One Size Fits All Approach: Recognizing the Heterogeneity of COPD

GOLD 2023 | Role of Underlying Inflammation in COPD Pathology and Clinical Features
Pulmonology
expert video

GOLD 2023 | Role of Underlying Inflammation in COPD Pathology and Clinical Features

What Are the Key Inflammatory Processes in Patients with COPD?
Pulmonology
expert video

What Are the Key Inflammatory Processes in Patients with COPD?

Burdens Experienced by Pediatric Asthma Patients and Their Caregivers
Pulmonology
expert video

Burdens Experienced by Pediatric Asthma Patients and Their Caregivers

Clinical Remission as a Goal in Asthma Clinical Practice
Pulmonology
expert video

Clinical Remission as a Goal in Asthma Clinical Practice

Concerns Surrounding OCS Side Effects in Patients With Severe Asthma
Pulmonology
expert video

Concerns Surrounding OCS Side Effects in Patients With Severe Asthma

Expert Insights: Importance of Lung Function Assessment in Pediatric Asthma Patients
Pulmonology
expert video

Expert Insights: Importance of Lung Function Assessment in Pediatric Asthma Patients

FeNO as a Biomarker for Type 2 Asthma
Pulmonology
expert video

FeNO as a Biomarker for Type 2 Asthma

How Can FeNO Support the Management of Pediatric Asthma?
Pulmonology
expert video

How Can FeNO Support the Management of Pediatric Asthma?

How Can Poor Lung Function Impact Asthma Burden in Adult Patients?
Pulmonology
videoanimation

How Can Poor Lung Function Impact Asthma Burden in Adult Patients?

IgE as a Biomarker for Type 2 Asthma
Pulmonology
expert video

IgE as a Biomarker for Type 2 Asthma

Importance of Lung Function Assessment in Adult Asthma Patients
Pulmonology
videoanimation

Importance of Lung Function Assessment in Adult Asthma Patients

Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management
Pulmonology
interactivity

Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management

Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction
Pulmonology
Infographic

Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction

On-Treatment Clinical Remission in Asthma Patients Case Tool
Pulmonology
interactivity

On-Treatment Clinical Remission in Asthma Patients Case Tool

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: DenmarkChange country/region